ArticleOncotarget2018

Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy.

Sutapa Sinha et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.